Greg Skidmore is a litigation partner in the Washington, D.C. office of Kirkland & Ellis, focusing on complex commercial litigation and appellate litigation in federal and state courts across the country.
Greg has represented clients in litigation matters involving a wide range of practice areas, including appellate, antitrust, bankruptcy, ERISA, the False Claims Act, government contracts, and administrative and regulatory. His representations have spanned a number of different industries, including pharmaceuticals, oil and gas, finance, aviation, insurance, defense contracting, telecommunications, and emerging technologies. Greg has resolved cases with motions practice, represented clients at trial and argued appeals in multiple federal appellate courts. He was named a "Rising Star" in Business Litigation and Antitrust Litigation by Super Lawyers magazine in 2014.
Commercial Litigation and Arbitration
Counsel for a major natural gas producer in a series of cases in state and federal court in Ohio. The United States District Court for the Northern District of Ohio granted summary judgment in favor of client, and the Sixth Circuit affirmed.
Counsel for Agility Defense & Government Services, a government contractor, in a three-week AAA arbitration arising out of a dispute over a U.S. Army contract worth $6 billion. Panel unanimously found in favor of our client and awarded damages.
Counsel for Nationwide Insurance defending claims arising out of Hurricane Ike. Resolved cases through successful motions practice and favorable settlements.
Counsel for a national commercial airline challenging on preemption grounds an attempt by a state to independently regulate the on-board service of alcoholic beverages.
Counsel for Boeing subsidiary against claims of monopolization and tying. On summary judgment, obtained dismissal of all antitrust claims.
Counsel for Barr Laboratories (now part of Teva Pharmaceuticals) defending an antitrust challenge to a so-called "reverse payment" settlement of Hatch-Waxman patent litigation regarding the drug Provigil® (modafinil).
Counsel for Barr Laboratories (now part of Teva Pharmaceuticals) defending antitrust challenges in federal court and California state court to a so-called "reverse payment" settlement of Hatch-Waxman patent litigation regarding the drug ciprofloxacin. In a split appeal, obtained affirmance of federal district court order granting summary judgment in both the Second Circuit and the Federal Circuit. The Supreme Court denied certiorari in both cases.
Henry v. Chesapeake Exploration, L.L.C., 739 F.3d 909, (6th Cir. 2014): after being retained on appeal, obtained a reversal of a district court ruling that an oil and gas lease held by the client had terminated for failure to conduct operations, and judgment was entered for the client.
Solis v. Malkani, 638 F.3d 269 (4th Cir. 2011): successfully argued for affirmance of a district court order awarding client fees for serving as an independent fiduciary appointed to oversee an ERISA plan.
Grayson v. AT&T, et al., 15 A.3d 219 (D.C. 2011) (en banc): in a case of first impression, authored successful en banc petition and brief arguing that District of Columbia courts, like federal courts, require a plaintiff to allege an injury-in-fact to have standing.
Terry v. Gaetz, No. 08-1183, 2009 WL 2382169 (7th Cir. 2009): on behalf of a pro bono client, successfully argued for reversal of a district court order dismissing as untimely a petition for writ of habeas corpus. In re W. R. Grace & Co., et al., No. 08-1044, 2009 WL 648651 (3d Cir. 2009): obtained affirmance of a bankruptcy court order dismissing certain claims against the estate.
Administrative and Regulatory
Southwest Airlines Co. v. Transportation Sec. Admin., 554 F.3d 1065 (D.C. Cir. 2009): on behalf of a major airline, successfully challenged part of a TSA order requiring airlines to overpay for the costs of airport security screening.
Teva Pharms. USA, Inc. v. Leavitt, No. 08-395-RML (D.D.C. Apr. 11, 2008): secured reversal of FDA decision denying client 180-day exclusivity for sales of its generic risperidone (Risperdal®) products.
Biovail Corp. v. FDA, 519 F. Supp. 2d 39 (D.D.C. 2007) and Biovail Corp. v. FDA, No. 06-cv-03355-RWT (D. Md. Dec. 21, 2006): successfully defended FDA approval of client's generic bupropion hydrochloride (Wellbutrin XL®) products.
Recipient, Kirkland & Ellis Pro Bono Service Award
Note, "Nebraska Legislative Bill 688: A Proposal to Pay College Football Players and the Impending Conflict with Title IX," 41 Harv. J. Leg. 319 (2004)Founder and Contributor, Sports Law Blog
United States Court of Appeals for the Second, Third, Fourth, Sixth, Seventh, Eighth, Ninth, District of Columbia and Federal Circuits
United States District Court for the District of Columbia
United States District Court for the District of Colorado
United States District Court for the Southern District of Texas
United States District Court for the Northern District of Ohio
District of Columbia Court of Appeals